PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1993 February; 86(2): 96–100.
PMCID: PMC1293859

The current debate concerning beta-agonists in asthma: a review.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. Br Med J. 1968 Feb 10;1(5588):335–339. [PMC free article] [PubMed]
  • Inman WH, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet. 1969 Aug 9;2(7615):279–285. [PubMed]
  • Sears MR, Rea HH. Patients at risk for dying of asthma: New Zealand experience. J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):477–481. [PubMed]
  • Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, Windom H, Beasley R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990 Mar;45(3):170–175. [PMC free article] [PubMed]
  • White PC, New MI, Dupont B. Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A. 1984 Apr;81(7):1986–1990. [PubMed]
  • Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991 Feb;46(2):105–111. [PMC free article] [PubMed]
  • Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. [PubMed]
  • Salome CM, Schoeffel RE, Woolcock AJ. Effect of aerosol and oral fenoterol on histamine and methacholine challenge in asthmatic subjects. Thorax. 1981 Aug;36(8):580–584. [PMC free article] [PubMed]
  • Kraan J, Koëter GH, vd Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985 Oct;76(4):628–636. [PubMed]
  • Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987 Apr;79(4):653–659. [PubMed]
  • Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. [PubMed]
  • van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CL. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990 Nov;86(5):793–800. [PubMed]
  • Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388–392. [PubMed]
  • Bel EH, Zwinderman AH, Timmers MC, Dijkman JH, Sterk PJ. The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax. 1991 Jan;46(1):9–14. [PMC free article] [PubMed]
  • van Schayck CP, Dompeling E, van Herwaarden CL, Folgering H, Verbeek AL, van der Hoogen HJ, van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. [PMC free article] [PubMed]
  • Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest. 1981 Apr;75(2):215–217. [PubMed]
  • Beswick KB, Pover GM, Sampson S. Long-term regularly inhaled salbutamol. Curr Med Res Opin. 1986;10(4):228–234. [PubMed]
  • Patakas D, Maniki E, Tsara V, Daskalopoulou E. Intermittent and continuous salbutamol rotacaps inhalation in asthmatic patients. Respiration. 1988;54(3):174–178. [PubMed]
  • Vandewalker ML, Kray KT, Weber RW, Nelson HS. Addition of terbutaline to optimal theophylline therapy. Double blind crossover study in asthmatic patients. Chest. 1986 Aug;90(2):198–203. [PubMed]
  • Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 1990 Dec 8;336(8728):1396–1399. [PubMed]
  • Tandon MK. Cardiopulmonary effects of fenoterol and salbutamol aerosols. Chest. 1980 Mar;77(3):429–431. [PubMed]
  • Scheinin M, Koulu M, Laurikainen E, Allonen H. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol. 1987 Nov;24(5):645–653. [PMC free article] [PubMed]
  • Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax. 1989 Feb;44(2):136–140. [PMC free article] [PubMed]
  • Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. Respiratory arrest in near-fatal asthma. N Engl J Med. 1991 Jan 31;324(5):285–288. [PubMed]
  • Harvey JE, Tattersfield AE. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax. 1982 Apr;37(4):280–287. [PMC free article] [PubMed]
  • Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol. 1982 Dec;70(6):417–422. [PubMed]
  • Hauck RW, Böhm M, Gengenbach S, Sunder-Plassmann L, Fruhmann G, Erdmann E. Beta 2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. Chest. 1990 Aug;98(2):376–381. [PubMed]
  • Page CP. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet. 1991 Mar 23;337(8743):717–720. [PubMed]
  • Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987 May;79(5):734–740. [PubMed]
  • Twentyman OP, Finnerty JP, Holgate ST. The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma. Am Rev Respir Dis. 1991 Oct;144(4):782–787. [PubMed]
  • Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet. 1990 Dec 1;336(8727):1338–1342. [PubMed]
  • Löfdahl CG, Chung KF. Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J. 1991 Feb;4(2):218–226. [PubMed]
  • Wallin A, Melander B, Rosenhall L, Sandström T, Wåhlander L. Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax. 1990 Apr;45(4):259–261. [PMC free article] [PubMed]
  • Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis. 1990 Sep;142(3):571–575. [PubMed]
  • Arvidsson P, Larsson S, Löfdahl CG, Melander B, Svedmyr N, Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J. 1991 Nov;4(10):1168–1173. [PubMed]
  • Jenkins MM, Hilton CJ, de Kock JC, Palmer JB. Exacerbations of asthma in patients on salmeterol. Lancet. 1991 Apr 13;337(8746):913–914. [PubMed]
  • Shepherd GL, Jenkins WJ, Alexander J. Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms. Lancet. 1991 Jun 8;337(8754):1424–1424. [PubMed]
  • Butchers PR, Skidmore IF, Vardey CJ, Wheeldon A. Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro. Br J Pharmacol. 1980;71(2):663–667. [PMC free article] [PubMed]
  • Persson CG, Ekman M, Erjefält I. Vascular anti-permeability effects of beta-receptor agonists and theophylline in the lung. Acta Pharmacol Toxicol (Copenh) 1979 Mar;44(3):216–220. [PubMed]
  • Tokuyama K, Lötvall JO, Löfdahl CG, Barnes PJ, Chung KF. Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage. Eur J Pharmacol. 1991 Jan 25;193(1):35–39. [PubMed]
  • Subramanian N. Inhibition of immunological and non-immunological histamine release from human basophils and lung mast cells by formoterol. Arzneimittelforschung. 1986 Mar;36(3):502–505. [PubMed]
  • Feldman RD, Hunninghake GW, McArdle WL. Beta-adrenergic-receptor-mediated suppression of interleukin 2 receptors in human lymphocytes. J Immunol. 1987 Nov 15;139(10):3355–3359. [PubMed]
  • Sears MR. Dose reduction of beta-agonists in asthma. Lancet. 1991 Nov 23;338(8778):1331–1332. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press